We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Turn £10k Into £30k With AstraZeneca plc

AstraZeneca plc (LON: AZN) would have trebled your money in 10 years.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

AstraZenecaIf you’d held AstraZeneca (LSE: AZN) (NYSE: AZN.US) shares over the past 12 months, you’d have done pretty nicely with a 40% rise to 4,544p.

A lot of that is down to the Pfizer bid, mind, but the turnaround plan put in place by new boss Pascal Soriot was already boosting the shares. And over three years you’d be sitting on a gain of more than 60%.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

But Fools are in it for the long term, so what would an investment in AstraZeneca a full 10 years ago be worth now?

Double your money

In September 2004, AstraZeneca shares were changing hands for around 2,265p, so if you’d invested £10,000 at the time you would have picked up 442 shares. Wind forward to today, and with AstraZeneca shares priced at 4,544p you’d have enjoyed a 101% capital gain — you’d have more than doubled your £10,000 in 10 years to £20,062.

Bear in mind that the period covered two traumatic events for AstraZeneca. One was the recession that hit the entire FTSE, but we also had the so-called patent cliff that saw the end of protection of some key drugs. Between late 2006 and early 2008, AstraZeneca shares lost a massive 49%, and investors could be forgiven for not being too impressed by the stock market at the time.

But even if you’d bought in at the very peak of 2006 and suffered the crunch, your shares would still be worth 30% more today! As failures go, I’ve seen worse.

Don’t forget the dividends

If that 10-year doubling impressed you, don’t forget there’s more to come in the shape of dividends. Early in the decade, AstraZeneca was handing out yields of between 2% and 3%, which was a little below the FTSE 100 average. But the dividend was on the rise, and by 2009 it was yielding 5% — and it got as high as 6.1% in 2011.

Altogether, the annual cash handout would have netted you an additional £5,617, giving you a total of £25,679 for an overall return of 157%.

But we don’t want to give you that!

Buy more shares!

No, if you hadn’t needed to spend your dividends, you’d have built an even bigger pot had you reinvested the cash in more AstraZeneca shares every year.

Just those few extra few shares every year would have added another £4,471 to your investment! That’s an extra 45% return on your original £10,000.

Your total gain with all dividends reinvested over 10 years? A pretty cool £30,150! And you’d be starting the next decade with 639 shares instead of your original 442.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Not sure what a SIPP is? 3 reasons it could pay to know!

Christopher Ruane digs into some of the details of a SIPP and highlights a trio of possible benefits he sees…

Read more »

Investing Articles

Lloyds shares have done nothing for almost half a year — are they stuck at £1?

Mark Hartley takes a closer look at why his Lloyds' shares have barely moved in 2026, but finds reassurance in…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Forget waiting for the IPOs: here’s how to invest in SpaceX and Anthropic today

SpaceX and Anthropic IPOs in 2026 are going to be huge. But investors don’t need to wait for them to…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

2 FTSE investment trusts to consider for passive income in 2026

Ben McPoland spotlights a pair of struggling investment trusts, one of which has crashed 50%. Why does he think they…

Read more »

Tesla car at super charger station
Investing Articles

How much impact could a SpaceX merger have on the Tesla share price?

A SpaceX IPO could be the biggest in history and if Musk's merger plans go ahead, it could save the…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£5,000 invested in Greggs shares 2 years ago is now worth…

Greggs' shares have been a diabolical investment over the last two years. But could they offer value today given they’ve…

Read more »

Investing Articles

Down 26% this year! Should I keep buying shares in this UK growth company?

Is Judges Scientific still one of the UK’s top growth shares? Stephen Wright thinks it might be – despite a…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Could these 3 income shares really turn £20,000 into £119,162?

James Beard explains how reinvesting dividends from income shares could create huge long-term wealth, including for those investors starting later…

Read more »